With immunotherapy now often being used in the first-line setting for advanced endometrial cancer, what is the role of immunotherapy in the second-line?

What second-line treatment would you recommend for a patient with recurrent endometrial cancer who received immunotherapy as part of front-line treatment?

• Utilize the same immunotherapy as indicated by patient's MMR status (e.g., if MMRp and received pembrolizumab before, use lenvatinib/pembrolizumab)
• Switch to the 'other' immunotherapy option, as indicated by patient's MMR status (e.g., if MMRd and received pembrolizumab before, use dostarlimab)
• Add another agent to immunotherapy regardless of MMR status (e.g., lenvatinib + immunotherapy even if MMRd)
• Do not re-use immunotherapy
• Other